ImmunoGen, Inc. (NASDAQ: IMGN) announces its next round of earnings Friday. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement.
Earnings and Revenue
Analysts are predicting ImmunoGen will report a loss of 31 cents per share on revenue of $13.84 million.
In the same quarter last year, ImmunoGen reported a loss per share of 37 cents on revenue of $8.48 million. Sales would be have grown 63.21 percent from the same quarter last year. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
|Quarter||Q2 2018||Q1 2018||Q4 2017||Q3 2017|
Over the last 52-week period, shares are down 5.89 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.
Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with ImmunoGen. The strength of this rating has maintained conviction over the past three months.
ImmunoGen's Q3 is scheduled to hold a conference call at 8:00 a.m. ET and it can be accessed here: https://edge.media-server.com/m6/p/bm3anrda
See more from Benzinga
- Q3 Earnings Outlook For American Axle & Mfg Hldgs
- Duke Energy's Q3 Earnings Preview
- Cinemark's Q3 Earnings Preview
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.